Integrated Analysis of Assays Drives Early Developability Assessment of Antibodies

May 5, 2025

Accelerate antibody developability assessment with an integrated, data‑driven approach that unifies complex assay outputs into a single, actionable framework. This poster demonstrates how Genedata streamlines biologics development by combining high‑throughput analytics with advanced sequence‑structural analysis software to reveal early liabilities and guide optimal molecule selection.

The Genedata platform supports modern drug discovery and development workflows by incorporating developability screening software, in silico screening software, and AI-driven developability prediction software into one end‑to‑end environment. With capabilities spanning Antibody informatics, ADC development, and generative AI protein design software, the platform enables scientists to rapidly evaluate molecular properties, compare candidates, and make confident decisions earlier in the pipeline.

Explore Genedata's integrated developability assessment platform empowers teams to operationalize AI in drug development, enhance data quality, and reduce cycle times—ultimately improving the success rate of next‑generation biologics.